Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery.
The authors present a case of an arteriovenous malformation of the central sulcus treated with Gamma Knife surgery. The patient developed perilesional edema 9 months after treatment and experienced severe headache and hemiparesis. Her symptoms were refractory to corticosteroid therapy and pain management. She was subsequently treated with bevacizumab with striking improvement in her symptoms and results of neuroimaging studies. This is the first time that bevacizumab has been used to control severe refractory perilesional edema related to an intracranial arteriovenous malformation.
Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA.
Brian J
BJ
Williams
Deric M
DM
Park
Jason P
JP
Sheehan
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D015901:Angiography, Digital Subtraction; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001929:Brain Edema / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006261:Headache / Q000209:etiology; D006801:Humans; D007091:Image Processing, Computer-Assisted; D002538:Intracranial Arteriovenous Malformations / Q000150:complications* / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D010291:Paresis / Q000209:etiology; D011183:Postoperative Complications / Q000188:drug therapy*; D016634:Radiosurgery / Q000009:adverse effects*; D013256:Steroids / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D013256:Steroids; D000068258:Bevacizumab